Intravenous thrombolysis by tenecteplase: Experience of the neurology department of Chu Hassan II Fez, Morocco

Abstract

Intravenous infusion of alteplase was the thrombolytic agent used for thrombolysis of ischemic stroke since 2010 in our neurology department.Tenecteplase was used as a thrombolytic agent for 127 patients in 2 years.The objective of our study is to determine the prevalence of Thrombolysis patients by Tenecteplase, to evaluate the length of care, the NIHSS scale before and after thrombolysis, the modified Rankin scale at 3 months, in order to assess the autonomy and the mortality rate. It’s a retrospective study involving a group of 127 patients over 2 years old, who have undergone intravenous Thrombolysis by tenecteplase in our department. The mean age was 67 years with a slight male predominance (69%). High blood pressure was the main cardiovascular risk factor. 38% of patients had a NIHSS between 8 and 14, 47% greater than 14. The average time to admit patients (from onset of symptoms to arrival in the emergency room) was 130 minutes. The average imaging time (from admission to the imaging room) was 22 minutes. The mean time to Thrombolysis (from admission to emergency at the start of treatment with rt-PA) was 69 minutes. The average time from onset of symptoms to treatment was 200 minutes.The main etiology for our patients was the cardio-embolic origin.The mean of the Rankin scale is not yet defined (our study is in progress). This study shows that tenecteplase before thrombectomy was associated with a high incidence of reperfusion and appears to be effective in thrombolysis among patients with ischemic stroke.